Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.



Pharmaceutical

Humanigen

Cameron Durrant

Yashmi Jogessar

henry madrid

Dale Chappell

The executive team at Humanigen has a history of experience in the commercial side of the pharmaceutical industry, with a focus on hematology and oncology. They have also worked in sales and marketing for companies such as Teva Pharmaceuticals and Schering-Plough. In addition, they have experience in global marketing from their time at Johnson & Johnson, and have also held positions in director of marketing and regional sales manager.

CEO and Executive Team

About

Team members

Other teams at Humanigen

Leadership Team

Board of Directors